Ranbaxy Laboratories Limited (RLL) has announced that the company's wholly owned subsidiary, Ranbaxy Pharmaceuticals Canada Inc. (RPCI) and Janssen-Ortho Inc. (JOI), have entered into a licensing and supply agreement for a generic fentanyl patch, sold under Ranbaxy's label, RAN Fentanyl Transdermal System.

This is the second product to be commercialised by RPCI as part of a licensing arrangement between the companies, a Ranbaxy release said.

Ran Fentanyl Transdermal System is classified as an opioid analgesic drug indicated for the management of persistent, moderate to severe chronic pain and is supplied in a patch form. The potential market for a generic fentanyl patch is expected to reach CAD 50 million. RAN Fentanyl Transdermal System will be available through pharmacies and wholesalers immediately.
Speaking on the licensing arrangement, Bill Abboud, president and general manager for RPCI, said, "This agreement, which also includes Risperidone, will provide Ranbaxy with an opportunity to commercialise products that continue to have a favorable impact on patient care, as well as on the Canadian healthcare system, and allow Ranbaxy to reinforce its presence in Canada."

Ranbaxy Pharmaceuticals Canada, Inc (RPCI) is a wholly owned subsidiary of RLL, and is engaged in the sale and distribution of generic medicines in the Canadian healthcare system. RPCI is the first India-based pharmaceutical company with a generic presence in Canada, the 8th largest pharmaceutical market in the world.